✦ LIBER ✦

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study

✍ Scribed by Chandra P Belani; Thomas Brodowicz; Tudor E Ciuleanu; Maciej Krzakowski; Sung Hyun Yang; Fábio Franke; Branka Cucevic; Jayaprakash Madhavan; Armando Santoro; Rodryg Ramlau; Astra M Liepa; Carla Visseren-Grul; Patrick Peterson; William J John; Christoph C Zielinski

Book ID: 117785859
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 230 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70339-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib versus placebo as maintenance

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

✍ Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shuju 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 371 KB

Maintenance therapy with pemetrexed plus

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

✍ Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujo 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 244 KB

Induction Pemetrexed and Cisplatin Follo

Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE)

✍ Domenico Galetta; Salvatore Pisconti; Saverio Cinieri; Giovanni Luigi Pappagallo 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 235 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB

Rationale and Design of MARQUEE: A Phase

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB